Self-Contained Laboratory Homogenizer Prepares Injectable Drugs

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2015
Volume 38
Issue 10
Pages: 14

GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications.

GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications, including nanoparticles, nanodispersions, nanoemulsions, and cell dispersions. The homogenizers can reduce particle sizes down to nanometer range for the preparation of injectable drugs.

The homogenizer is designed for continuous operation up to 1500 bar. The sanitary design is suited for clean-in-place and sterilization-in-place. The Pony NS2006L achieves the same results as larger size homogenizers, and its compact design allows easy installation with simple operation and quick maintenance. It is also suitable for viscous products.

GEAwww.gea.com
 

Articles in this issue
Fig.1b-Graph-GZD_495forweb.jpg
Identifying Powder Properties that Define Process Performance
Connecting MES to Process Control
Connecting MES to Process Control
PHT1015_PackForum_NJMphoto_300forweb.jpg
Parenteral Packaging Advances
Serialization Shake Out
Investigating Biologics
Advances in Fluorination Chemistry for API Synthesis
Advances in Fluorination Chemistry for API Synthesis
PT1015_ADD_artwork.jpg
Regulatory Considerations for Alcohol-Induced Dose Dumping of Oral Modified-Release Formulations
BP1015_Perspectives_Figure1-New-1444064165242.jpg
Small-Molecule API CMOs Are Thriving
NETZSCH_Alpha_22_225.jpg
Modular Platform for Agitator Bead Mill Optimizes Grinding
GEA_Pony-2006A2_225.jpg
Self-Contained Laboratory Homogenizer Prepares Injectable Drugs
Mitos_System-2_225.jpg
Microfluidics Systems Designed for Flow-Chemistry Experiments
Ross-SysCon-225.jpg
Control Systems
Till-Alice120-New-1444331636184.jpg
Evolving to Meet Industry Changes
Stretching Product Value through Reformulation Strategies
Stretching Product Value through Reformulation Strategies
Characterization and Formulation Screening of mAb and ADCs by High-Throughput DLS
Characterization and Formulation Screening of mAb and ADCs by High-Throughput DLS
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

ACG to Showcase Sustainability Innovations at Pharmapack Europe 2025

Susan Haigney
January 21st 2025
Article

The company will be featuring its sustainable packaging solutions at the event in Paris on Jan. 22–23, 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

Feliza Mirasol
January 17th 2025
Article

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

PackGene and GC4K Team Up Along with Weill Cornell Medicine for Gene Therapy to Treat Rare Neurological Disease

Feliza Mirasol
January 11th 2025
Article

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

Feliza Mirasol
January 7th 2025
Article

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.